UOC
UBS O'Connor Portfolio holdings
AUM
$1.93B
1-Year Return
38.75%
This Quarter Return
+9.04%
1 Year Return
+38.75%
3 Year Return
+182.42%
5 Year Return
+480.25%
10 Year Return
+1,573.29%
AUM
$5.59B
AUM Growth
+$865M
(+18%)
Cap. Flow
+$450M
Cap. Flow
% of AUM
8.05%
Top 10 Holdings %
Top 10 Hldgs %
66.42%
Holding
655
New
83
Increased
132
Reduced
97
Closed
122
Top Buys
| 1 |
ATVI
Activision Blizzard Inc.
ATVI
|
+$800M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$386M |
| 3 |
NEWR
New Relic, Inc.
NEWR
|
+$274M |
| 4 |
DEN
Denbury Inc.
DEN
|
+$189M |
| 5 |
VMW
VMware, Inc
VMW
|
+$172M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$230M |
| 2 |
PDCE
PDC Energy, Inc.
PDCE
|
+$221M |
| 3 |
UNVR
Univar Solutions Inc.
UNVR
|
+$219M |
| 4 |
FOCS
Focus Financial Partners Inc. Class A
FOCS
|
+$146M |
| 5 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$141M |
Sector Composition
| 1 | Technology | 34.96% |
| 2 | Healthcare | 28.93% |
| 3 | Real Estate | 5.18% |
| 4 | Financials | 4.45% |
| 5 | Consumer Discretionary | 4.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Precision BioSciences
DTIL
$58.6M
| $456K | 0.01% |
44,610
| – | – |
|
377
Context Therapeutics
CNTX
$75.8M
| $447K | 0.01% |
295,700
+230,072
| +351% | +$347K |
|
378
BioNTech
BNTX
$24.5B
| $435K | 0.01% |
+4,000
| New | +$435K |
|
|
UBX
379
DELISTED
Unity Biotechnology
UBX
| $430K | 0.01% |
179,080
| – | – |
|
380
Sonos
SONO
$1.78B
| $420K | 0.01% |
+32,500
| New | +$420K |
|
381
NewAmsterdam Pharma
NAMS
$2.83B
| $416K | 0.01% |
+45,000
| New | +$416K |
|
382
Monte Rosa Therapeutics
GLUE
$296M
| $409K | 0.01% |
85,478
-15,000
| -15% | -$71.9K |
|
|
EDR
383
DELISTED
Endeavor Group Holdings, Inc.
EDR
| $398K | 0.01% |
+20,000
| New | +$398K |
|
384
Aura Biosciences
AURA
$402M
| $395K | 0.01% |
44,000
| – | – |
|
|
AFMD
385
DELISTED
Affimed
AFMD
| $392K | 0.01% |
82,000
+47,910
| +141% | +$229K |
|
386
CareTrust REIT
CTRE
$7.68B
| $385K | 0.01% |
18,800
-6,470
| -26% | -$133K |
|
387
Essex Property Trust
ESS
$17.1B
| $382K | 0.01% |
1,800
-34,700
| -95% | -$7.36M |
|
388
Mersana Therapeutics
MRSN
$35.1M
| $376K | 0.01% |
+11,857
| New | +$376K |
|
389
Galapagos
GLPG
$2.21B
| $376K | 0.01% |
10,888
-46,000
| -81% | -$1.59M |
|
390
Equinix
EQIX
$74.9B
| $363K | 0.01% |
+500
| New | +$363K |
|
391
Vir Biotechnology
VIR
$721M
| $356K | 0.01% |
+38,000
| New | +$356K |
|
|
ROIC
392
DELISTED
Retail Opportunity Investments Corp.
ROIC
| $342K | 0.01% |
27,600
-554,094
| -95% | -$6.86M |
|
393
CytomX Therapeutics
CTMX
$360M
| $335K | 0.01% |
259,965
| – | – |
|
394
Penumbra
PEN
$11.1B
| $331K | 0.01% |
1,369
| – | – |
|
395
Expedia Group
EXPE
$26.9B
| $309K | 0.01% |
3,000
-117,500
| -98% | -$12.1M |
|
396
Avantor
AVTR
$8.75B
| $305K | 0.01% |
14,470
-93,000
| -87% | -$1.96M |
|
397
Leap Therapeutics
LPTX
$11.8M
| $303K | 0.01% |
219,434
+80,000
| +57% | +$110K |
|
398
Acumen Pharmaceuticals
ABOS
$87.2M
| $289K | 0.01% |
69,538
-10,000
| -13% | -$41.5K |
|
399
RingCentral
RNG
$2.94B
| $271K | ﹤0.01% |
9,155
-1,000
| -10% | -$29.6K |
|
|
VZIO
400
DELISTED
VIZIO Holding Corp.
VZIO
| $271K | ﹤0.01% |
50,000
-150,000
| -75% | -$812K |
|